WHO Grade 3 Glioma — Trials

WHO Grade 3 Glioma — Trials · CancerIndex

Clinical trials

Registered studies

258 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 57
Recruiting: 32
Ph III recruiting: 2
Growth YoY: —
Industry share: 11%
Top sponsor: National Cancer Institute (NCI)
Termination share: 39.4%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (53)

clinicaltrialsPublishedShowing 1–6 of 6 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT03212274	Olaparib in Treating Patients With Advanced Glioma, Cholangiocarcinoma, or Solid Tumors With IDH1 or IDH2 Mutations	active not recruiting	Phase 2	89	National Cancer Institute (NCI)NIH	1	Sep 9, 2026	clinicaltrials
NCT05859334	Testing the Anti-cancer Drug Erdafitinib for Brain Cancers That Have Returned or Progressed Following Treatment	active not recruiting	Phase 2	30	National Cancer Institute (NCI)NIH	1	Aug 17, 2026